- Home
- CTRM vs CGTX Comparison
CTRM vs CGTX Comparison
Compare CTRM & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTRM
- CGTX
- Stock Information
- Founded
- CTRM 2016
- CGTX 2007
- Country
- CTRM Cyprus
- CGTX United States
- Employees
- CTRM N/A
- CGTX 25
- Industry
- CTRM Marine Transportation
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- CTRM Consumer Discretionary
- CGTX Health Care
- Exchange
- CTRM Nasdaq
- CGTX Nasdaq
- Market Cap
- CTRM 25.0M
- CGTX 17.2M
- IPO Year
- CTRM N/A
- CGTX 2021
- Fundamental
- Price
- CTRM $2.38
- CGTX $0.44
- Analyst Decision
- CTRM
- CGTX Strong Buy
- Analyst Count
- CTRM 0
- CGTX 6
- Target Price
- CTRM N/A
- CGTX $8.30
- AVG Volume (30 Days)
- CTRM 51.4K
- CGTX 2.8M
- Earning Date
- CTRM 03-18-2025
- CGTX 05-06-2025
- Dividend Yield
- CTRM N/A
- CGTX N/A
- EPS Growth
- CTRM N/A
- CGTX N/A
- EPS
- CTRM 2.39
- CGTX N/A
- Revenue
- CTRM $76,443,340.00
- CGTX N/A
- Revenue This Year
- CTRM N/A
- CGTX N/A
- Revenue Next Year
- CTRM N/A
- CGTX N/A
- P/E Ratio
- CTRM $1.01
- CGTX N/A
- Revenue Growth
- CTRM N/A
- CGTX N/A
- 52 Week Low
- CTRM $2.33
- CGTX $0.34
- 52 Week High
- CTRM $5.49
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- CTRM 40.22
- CGTX 25.38
- Support Level
- CTRM $2.37
- CGTX $0.36
- Resistance Level
- CTRM $2.84
- CGTX $0.45
- Average True Range (ATR)
- CTRM 0.15
- CGTX 0.05
- MACD
- CTRM 0.00
- CGTX -0.01
- Stochastic Oscillator
- CTRM 15.69
- CGTX 17.03
About CTRM Castor Maritime Inc.
Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under two reportable segments namely Dry bulk; Aframax/LR2 tanker; Handysize tanker and Container ship. It generates maximum revenue from the Dry bulk segment.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.